Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

NCT00454363 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

NIH

Sponsor class

Conditions

Gastrin-Producing Neuroendocrine Tumor
Lung Carcinoid Tumor
Metastatic Digestive System Neuroendocrine Tumor G1
Multiple Endocrine Neoplasia Type 1
Pancreatic Glucagonoma
Pancreatic Insulinoma
Pancreatic Polypeptide Tumor
Recurrent Digestive System Neuroendocrine Tumor G1
Recurrent Pancreatic Neuroendocrine Carcinoma
Regional Digestive System Neuroendocrine Tumor G1
Somatostatin-Producing Neuroendocrine Tumor

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Pazopanib Hydrochloride
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)